Video

leva Pelvic Health System shows efficacy for improving symptoms of urinary incontinence

Author(s):

Urology Times staff

“We had fantastic completion of the study, and we were very pleased with the results,” says Samantha Pulliam, MD.

In this video, Samantha Pulliam, MD, discusses the background and key findings for the Obstetrics & Gynecology study, “Digital therapeutic device for urinary incontinence: a randomized controlled trial.” Pulliam is chief medical officer for Renovia Inc.

Related Videos
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
Hailey Frye answers a question during a Zoom video interview
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Related Content
Neuromodulation device shows promising efficacy for neurogenic bladder
April 16th 2025

Neuromodulation device shows promising efficacy for neurogenic bladder

Hannah Clarke
Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Faceless view of senior man talking to doctor in bright light while taking notes on clipboard | Image Credit: © DragonImages - stock.adobe.com
April 3rd 2025

Kiran Sury, MD, on implementing ProACT for incontinence

Kiran Sury, MD
"In terms of making it a safe, highly reliable operation, if you're comfortable with slings and sphincters, you are very well positioned to learn this surger," says Kiran Sury, MD.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury
March 14th 2025

Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury

Hannah Clarke
The 52-week study plans to enroll 16 patients across 4 sites in the US.
FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI
March 4th 2025

FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI

Hannah Clarke
The ARID II trial is assessing the safety and effectiveness of the device in men who are scheduled to undergo robotic-assisted radical prostatectomy.
© 2025 MJH Life Sciences

All rights reserved.